当前位置: X-MOL 学术Semin. Thromb. Hemost. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Hemostatic Biomarkers and Cancer Prognosis: Where Do We Stand?
Seminars in Thrombosis and Hemostasis ( IF 5.7 ) Pub Date : 2021-08-27 , DOI: 10.1055/s-0041-1733925
Anna Falanga 1, 2 , Marina Marchetti 1 , Laura Russo 1
Affiliation  

Cancer patients are characterized by hypercoagulable state and an increased rate of thrombotic events, the most common being venous thromboembolism. Several hemostatic pathways that are significantly implicated in mechanisms of thromboembolic disease are also involved in growth, invasion, and metastatic spread of malignant cells as well in tumor-induced neo-angiogenesis. This close connection between cancer and the hemostatic system has prompted numerous studies on the role of alterations in the level plasma biomarkers of the different compartments of hemostasis in predicting cancer prognosis. In this review, we collect the results of several exemplificative studies that have evaluated clotting activation biomarkers in relation to different cancer outcomes with a final emphasis on current research and forthcoming directions in this field.



中文翻译:

止血生物标志物和癌症预后:我们站在哪里?

癌症患者的特征是高凝状态和血栓事件发生率增加,最常见的是静脉血栓栓塞。与血栓栓塞性疾病机制显着相关的几种止血途径也参与恶性细胞的生长、侵袭和转移扩散以及肿瘤诱导的新血管生成。癌症与止血系统之间的这种密切联系促使人们开展了大量关于不同止血区室的血浆生物标志物水平变化在预测癌症预后中的作用的研究。在这篇综述中,我们收集了几项示例性研究的结果,这些研究评估了与不同癌症结果相关的凝血激活生物标志物,最后强调了该领域的当前研究和未来方向。

更新日期:2021-08-29
down
wechat
bug